The Research On R&d Information Disclosure Of China's Pharmaceutical Industry

With the rapid development of China's economy and the intensification of market competition,research and development ability has become the core competitiveness of enterprises,research situation has also become one of the main factors when the public consider the growth of enterprises.Since the new version of "Accounting Standards for Business Enterprises" in 2006 has changed the accounting treatment of enterprise research and development expenses,the content related to the research and development expenses has attracted more and more attention by scholars and investors.At present,there are many scholars in our country to discuss the hot topic of R&D expenditure,and they more concentrated in accounting treatment the cost,the relationship between R&D information disclosure and company value,R&D investment and earnings management,etc.However,there are few studies on the standardization and completeness of the research and development information of the enterprises in our country,and the researches on specific industries is rarer.Different industries have different characteristics of the research and development activities,further research in a specific industry can not only enrich the theoretical results,but also provide more targeted guidance practice.This paper mainly studies the status quo of information disclosure about R&D expenditure in pharmaceutical industry.The author selected the 2015 annual report of the pharmaceutical manufacturing public company,which lists in Securities industry as a sample,based on the relevant provisions of the Ministry of Finance and the China Securities Regulatory Commission on the disclosure of the research and development expenditure information of listed companies.This paper statisticed the disclosure of information about the research and development investment in board reports and financial reports of public company in pharmaceuticals industry.At the same time,combined with the analysis of the case of ChinaResources Sanjiu Medical&Pharmaceutical Co.,Ltd.,the author summed up the current situation of China's pharmaceutical industry R&D expenditure information disclosure and problems.Aiming at problems,the author put forward several suggestions.According the studies,the vast majority of Chinese pharmaceutical listed companies separately disclosed the research and development spending in board reports.However,they had seldom disclosed the situation of the research and development project had paid no attention to the format and abnormal fluctuation of related data.Disclosure of the new annual research and development plan is also less.In the financial report,according to the statistical analysis,the author found that there are many problems of the pharmaceutical manufacturing public company when they disclosed R&D information.For example,accounting policies on the costs of research and development are not specific enough;The industry is lack of uniform standards;The disclosure of proportion of intangible assets,which through internal research and development,in final intangible assets,is poor;"Development expenditure" account details are lack of specification;Articulation in annual report is not clear.Aiming at the above problems,the author suggests,if we want to optimize the disclosure of information about China Pharmaceutical Industry R&D expenditure,relevant departments should improve system and strengthen supervision,at the same time,enterprises should execute strictly.